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Abstract: Background. We established multiple University
of Michigan Squamous Cell Carcinoma (UM-SCC) cell lines.
With time, these have been distributed to other labs all over
the world. Recent scientific discussions have noted the need
to confirm the origin and identity of cell lines in grant proposals
and journal articles. We genotyped the UM-SCC cell lines in
our collection to confirm their unique identity.
Method. Early-passage UM-SCC cell lines were genotyped
and photographed.
Results. Thus far, 73 unique head and neck UM-SCC cell
lines (from 65 donors, including 21 lines from 17 females) were
genotyped. In 7 cases, separate cell lines were established
from the same donor.
Conclusions. These results will be posted on the UM Head
and Neck SPORE Tissue Core website for other investigators
to confirm that the UM-SCC cells used in their laboratories
have the correct features. Publications using UM-SCC cell lines
should confirm the genotype. VC 2009 Wiley Periodicals, Inc.
Head Neck 32: 417–426, 2010
Keywords: head and neck squamous carcinoma, human,
unique cell lines; genotyping; tetranucleotide repeats; UM-SCC
Head and neck squamous cell cancers
(HNSCCs) account for 11,170 deaths annually in
the United States and nearly 250,000 deaths
annually worldwide. HNSCC cell lines devel-
oped from patients with cancers of various sites
in the head and neck region1 have been distrib-
uted to a wide array of institutions to study
this disease. The squamous cell carcinoma cell
lines developed at the University of Michigan
(UM-SCCs) have been among the most widely
used because many specific characteristics are
known—such as relative radiation sensitivity,2
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p53 mutation status,3 karyotype,4 antigen
expression,5,6 cisplatin sensitivity,3 and integrin
expression and activation7–12—that make these
useful tools for other investigators. Until now
these cell lines have not undergone extensive
genetic fingerprinting analysis, which makes it
difficult to readily confirm the identity of the
individual cell lines.
Cell line identity can be derived from several
different methods, including sequencing of DNA
polymorphisms,13 karyotyping,14 and sequencing
of hypervariable mitochondrial sequences,15 and
some groups have even suggested TP53 sequenc-
ing16 because the gene is frequently mutated in
human cancers.17,18 Unfortunately, these methods
are limited by the time it takes to produce mean-
ingful results, the expense of each protocol, and/
or the value of the data. For example, TP53
sequencing cannot be used to distinguish the
identity of cell lines when the gene is wild type.
Because of this, cross-contamination has
become a frequent problem for researchers. For
example, 45 of 252 novel cell lines (18%) col-
lected in the German Cell Line Bank were
found to have nonunique genotypes.19 Thus,
many researchers have concluded that there is
a need for a rapid and standardized universal
method for cell line identification.20–23
Despite the realization that genetic verifica-
tion is a necessary component of cell line
research, until recently, cell line genotyping was
not reliable because some transformed tissue cul-
tures have defective mismatch repair pathways,
leading to increased microsatellite instability24
and thus preventing reliable genotyping. Microsa-
tellites are short tandem repeat (STR) loci that
are highly polymorphic repetitive DNA sequence
elements 2 to 7 nucleotides in length.25,26 These
STR loci are distributed throughout the human
genome and alleles of STR loci can be differenti-
ated by the number of repeat sequence (2–7 nu-
cleotides long) copies located at each locus.27
Because polymerase chain reaction (PCR)–based
methods can be used to amplify STR loci,
researchers have used radioactive, silver stain or
fluorescence-based methods to detect STR loci
length, after separation of the different alleles by
electrophoresis. Many of these loci are made up
of dinucleotide repeats that are susceptible to
instability and polymerase slippage during PCR
amplification.28 The advent of commercially avail-
able assays based on amplifying tetranucleotide
STR sequences, which have greater intrinsic sta-
bility than that of dinucleotide repeats, provides
a much more reliable means of genetic identifica-
tion.28,29 As such, STR profiling has become a
common reference for most commercially avail-
able cell lines.23 Here, we present genotyping
data obtained with 9 common tetranucleotide
repeat sequences and the AMEL locus (which dif-
fers in length on the X and Y chromosomes) on
73 UM-SCC head and neck cell lines.
MATERIALS AND METHODS
Cell Culture. All of the UM-SCC cell lines were
established from head and neck cancer patients
who gave written informed consent in studies
reviewed and approved by the University of
Michigan Medical School Institutional Review
Board. Current and early-passage human UM-
SCC cell lines established at the University of
Michigan1–3,5,30 were retrieved from liquid nitro-
gen storage. Cell lines were grown in complete
Dulbecco’s modified Eagle’s medium (cDMEM;
Sigma Chemical Co, St. Louis, MO) containing 2
mM L-glutamine, 1% nonessential amino acids,
1% penicillin-streptomycin (Invitrogen, Carls-
bad, CA), and 10% fetal bovine serum, in a
humidified atmosphere of 5% CO2 at 37
C. All
cell lines were tested for mycoplasma, using the
MycoAlert Detection Kit (Cambrex, Rockland,
ME). Contaminated cultures were treated with
Plasmocin (InvivoGen, San Diego, CA) in accord
with the manufacturer’s protocol, and testing
was repeated at monthly intervals.
Genomic DNA Purification. Exponentially grow-
ing (60% to 80% confluence) cells were trypsi-
nized and washed in phosphate-buffered saline.
Cell pellets were flash frozen at 80C; resus-
pended in 500 lL of 0.1 M Tris (pH 8.0), 0.1 M
ethylene diamine tetraacetic acid (EDTA), 0.4 M
NaCl, 1% sodium dodecyl sulfate, and 0.3 mg/
mL proteinase K (New England Biolabs, Ips-
wich, MA); and incubated overnight at 55C. Af-
ter incubation, 500 lL of phenol/chloroform (pH
6.7) was added (Fisher Scientific, Pittsburg, PA),
and the dissolved cells were centrifuged for 10
minutes at 1700  g. The upper phase contain-
ing the DNA was transferred to a new tube with
150 lL of 7.5 M ammonium acetate and 800 lL
of 100% ethanol. The precipitated DNA was
pelleted by centrifugation for 2 minutes at
1700  g. DNA pellets were washed with 70%
ethanol, air dried, and resuspended in high-
performance liquid chromatography–grade H2O.
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Analysis of Genetic Loci. DNA samples were
diluted to 0.10 ng/lL and were analyzed at the
University of Michigan DNA Sequencing Core
using the Profiler Plus PCR Amplification Kit
(Applied Biosystems, Foster City, CA) in accord
with the manufacturer’s protocol. The 9 loci
D3S1358, D5S818, D7S820, D8S1179, D13S317,
D18S51, D21S11, FGA, and vWA, and the ame-
logenin locus were analyzed and compared with
ladder control samples.
RESULTS
Genetic Profiling of UM-SCC Cell Lines. For each
of the genotyped cell lines now represented
in the UM Head and Neck SPORE cell line
bank, the UM-SCC cell line number, the donor
sex, the anatomic tumor site (specimen site and
primary tumor location), the passage number of
the genotyped cell line that was included in the
SPORE tissue core freezer, and the alleles for
each of the following microsatellite loci: AMEL,
D3S1358, D5S818, D7S820, D8S1179, D13S317,
D18S51, D21S11, FGA, and vWA are given in
Table 1. The amelogenin locus on the X and Y
chromosomes is used for sex identification; how-
ever, because some cell lines and even normal
cells from older male donors lose the Y chromo-
some,4,31–33 an AMEL-X genotype does not con-
firm that the donor is female. However, the
presence of a Y signal was observed only in
HNSCC cell lines derived from male donors. Of
the 65 patient donors, 17 of 65 were females
(26%).
In several cases it was possible to derive >1
cell line from the same donor.1 In some cases,
these were from different sites during the same
procedure (UM-SCC-17A from the endolarynx;
UM-SCC-17B from tumor extending outside the
thyroid cartilage34; UM-SCC-22A from the pri-
mary site; UM-SCC-22B from a lymph node me-
tastasis) or from different surgical procedures
(UM-SCC-10A from the larynx at the time of
laryngectomy and UM-SCC-10B from a submen-
tal lymph node metastasis 10 months later; UM-
SCC-11A pretreatment biopsy; UM-SCC-11B
post chemotherapy surgery; UM-SCC-14A wide
local excision after excisional biopsy; UM-SCC-
14B recurrence after surgery and radiation;
UM-SCC-14C skin metastasis after chemother-
apy; UM-SCC-74A surgical resection after chem-
otherapy and radiation; UM-SCC-74B second
surgery for persistent cancer; UM-SCC-81A la-
ryngeal primary; UM-SCC-81B tonsil primary).1
With a few exceptions the lines from the same
donor exhibited the same genetic profile.
Losses of single alleles at individual loci
were fairly common in the cell lines. This pat-
tern of allelic loss is consistent with prior karyo-
type studies,4,34–36 and loss of heterozygosity
studies with these cell lines that revealed
frequent losses of individual chromosome
arms.37–39 In some cases we noted loss of an al-
lele in 1 but not both of the cell lines derived
from the same donor. For example, in UM-SCC-
17A and -17B, allele 17 at D18S51 was lost in
UM-SCC-17B but not in UM-SCC-17A. UM-
SCC-81A and -81B are perhaps the most unlike
each other of all of the paired sets. These cell
lines were considered to be from 2 separate pri-
mary tumors of the same donor that arose 5
years apart: the first from the larynx and the
second from the tonsil. In this pair there were
differences at 7 loci, although the genotype of
each is consistent with the same donor origin of
the cell lines. The cell lines share at least 1 al-
lele at each locus with a single exception. At
AMEL UM-SCC-81A but not -81B lost the Y
chromosome signal. At D3S1358, UM-SCC-81A
has allele 15, -81B does not; at FGA -81B has al-
lele 20, -81A does not; at D8S1779 -81B has 13,
-81A does not; at D18S51 81A has 19, -81B does
not; at D13S317 81B has 11, -81A does not. The
most interesting difference was at D21S11,
where -81A has 33.2, whereas -81B has 29. We
suspect that the donor’s normal complement
was allele 29, and 33.2 at this locus, but each
tumor lost a different allele.
Genetic drift over time in cultured cell lines
has been raised as a major concern for scientists
using established cell lines. We had previously
assessed the karyotype of cultured SCC cell
lines over numerous passages and found re-
markable stability.34 In the present study, com-
parison of allelic patterns in 3 different cell
lines taken at low passage and >50 passages
revealed no changes in the distribution of
alleles, suggesting stability at each locus
(Table 2). However, in high-passage UM-SCC-1,
allele amplicons for AMEL-Y and FGA-22 were
lost, and, in high-passage UM-SCC-22A, 1 wVA-
15 allele was lost.
To further characterize the ability of this
assay to discriminate genotypes between cancer
cell lines and normal human fibroblasts, we gen-
otyped short-term cultured fibroblasts from the
donors of UM-SCC-11, -26, and -42, and then we
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compared the results to the genotypes of the
cancer cell lines. As shown in Table 3, many of
the alleles that were lost during either malig-
nant transformation of cell culture were present
in the fibroblast line. For example, UM-SCC-
11A has 7 loci that appear to have either homo-
zygous or lost alleles and UM-SCC-11B appears
to have 9 loci with only a single marker. How-
ever, genotyping of the donor fibroblast line
revealed that only D21S11 has a single allele.
Thus, only this allele is potentially homozygous
or lost during culture. Analysis of the fibroblast
data reveals that the UM-SCC cancer cell lines
occasionally gain or lose a single allele at vari-
ous loci. For example, in both UM-SCC-26 and
UM-SCC-42, 4 alleles are lost at 4 different loci
in each cancer cell line compared with the donor
fibroblast line.
Representative photomicrographs of UM-
SCC cell lines are shown in Figure 1 to illus-
trate the various in vitro morphologies typically
exhibited by individual cell lines. Additional
photographs of UM-SCC cell lines are also
reported in 2 book chapters for comparison.40,41
Note that changes occur with increasing cell
density in some cell lines. For example, UM-
SCC-5 and UM-SCC-17A grow as tightly packed
colonies. UM-SCC-17B has a morphology similar
to that of UM-SCC-17A, but the cells are less
inclined to pack tightly, especially shortly after
passage. UM-SCC-74A and -74B are from a
patient previously treated with chemotherapy,
and radiation and the cells in both cultures
have undergone epithelial-mesenchymal transi-
tion, giving the culture a fibroblastoid appear-
ance. This is consistent with the sarcomatoid
morphology sometimes observed in tissue sam-
ples from recurrent SCC after radiation.
It was not possible to retrieve viable isolates
for some of the original UM-SCC cell lines from
liquid nitrogen storage. However, we did geno-
type the DNA from these nonviable cells so
that if others have healthy cultures of the UM-
SCC cell lines no longer available in our bank,
the correct genotype of the original cell line is
provided. Such examples (UM-SCC-15, -20, and
-27) are marked in Table 1 with an asterisk.
We discovered several examples of mislabeled
cell lines within our own bank. However, for
each of the mislabeled cell lines, we retrieved
early-passage vials from our bank and found
unique genotypes for each cell line. These were
expanded and used to repopulate the tissue
core bank.
Table 2. Genotyping results after long-term cell culture.
Cell line Passage AMEL D3S1358 vWA FGA D8S1179 D21S11 D18S51 D5S818 D13S317 D7S820
UM-SCC-1 4 X, Y 18 15, 18 18, 22 13, 16 27 18 10, 13 8, 11 9, 12
UM-SCC-1 >150 X 18 15, 18 18 16 27 18 10, 13 8, 11 9, 12
UM-SCC-2 6 X 16 16 19 12, 14 30, 33.2 18 12 11, 13 8, 12
UM-SCC-2 62 X 16 16 19 12, 14 30, 33.2 18 12 11, 13 8, 12
UM-SCC-22A 16 X 16 15, 18 22, 24 11, 13 28 18 12 8, 12 8, 9
UM-SCC-22A 138 X 16 18 22, 24 11, 13 28 18 12 8, 12 8, 9
Abbreviation: UM-SCC, University of Michigan Squamous Cell Carcinoma cell line series.
Note: Genotyping results for 3 UM-SCC cell lines at high and low passages demonstrate that alleles may be lost as a result of in vitro evolution of the
population.
Table 3. Genotyping results of 3 fibroblast and cancer cell lines from matched donors.
Cell line Passage AMEL D3S1358 vWA FGA D8S1179 D21S11 D18S51 D5S818 D13S317 D7S820
UM-SCC-11 fibroblasts 1 X, Y 14, 16 16, 17 19, 24 12, 15 28 16, 18 11, 12 12, 14 10, 11
UM-SCC-11A 10 X 16 16, 17, 18 19, 24 12, 15 28 16 11 14 11
UM-SCC-11B 38 X 16 16, 17, 18 19 15 28 16 11 14 11
UM-SCC-26 fibroblasts 2 X, Y 16, 17 16, 17 21, 24 13, 15 31, 32.2 14, 18 10, 11 11, 12 7, 12
UM-SCC-26 10 X, Y 16 16, 17 21, 24 13, 15 32.2 14 10, 11 11 7, 12
UM-SCC-42 fibroblasts 7 X, Y 15, 16 18 19, 20 10, 14 29, 30 12, 15 11, 12 12, 13 11, 12
UM-SCC-42 7 X 16 18 19, 20 10, 14 29, 30 12 11, 12 13 11, 12
Abbreviation: UM-SCC, University of Michigan Squamous Cell Carcinoma cell line series.
Note: For the UM-SCC-11, -26, and -42 cell lines,we were able to grow and genotype fibroblasts from the donor. In each case, the matched genotypes
are shown. Donors with heterozygous alleles for each locus have 2 numbers corresponding to different alleles. Where only a single allele is listed,
either the patient had homozygous alleles at the given locus, an allele was not amplified (false negative), or was lost from tumor chromosome instability
cloned out in the process of cell line establishment.
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DISCUSSION
A lack of vigilance in cell acquisition and iden-
tity testing has plagued scientific studies and
publications since the inception of cell line
methods.42–47 In the 1970s and 1980s, examples
of interspecies and intraspecies cross-contamina-
tion of human cell lines was documented by Nel-
son-Rees.43,45 Data produced from cross-
contaminated heterogeneous populations of
cells, or incorrectly identified cell lines that
might be from a different tumor type or even
the wrong species, lead to incorrect conclusions,
FIGURE 1. Representative photomicrographs. University of Michigan squamous cell carcinoma (UM-SCC) cell lines were cultured for
24 hours before photographs were captured under either a 10 (UM-SCC-1) or 40 objective lens (remaining cell lines). In all cases,
genotyped cell lines were imaged.
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experimental results that are not representative
of a particular tumor or tissue type, confusion
in the literature, and a general mistrust of data
produced with cell lines. In 2004, for example, 1
study reported that 9% of 483 researchers used
cultures containing HeLa contaminants.49 Addi-
tionally, we performed a simple literature search
for scientific papers that compared parental
MCF-7 cells with an adriamycin-resistant cell
line thought to be derived from MCF-7, called
MCF-7/Adr. This search revealed 187 different
papers, some of which have gone on to propose
the use of novel chemotherapeutics in specific
patient populations. However, it has recently
been shown that MCF-7/Adr is actually an ovar-
ian carcinoma cell line,48 meaning that most of
the data analysis between 2 cell lines is com-
pletely invalid.
Despite the critical nature of correctly identi-
fied cell lines as model systems, it has been diffi-
cult to get funding for cell line characterization,
leaving researchers who realize the importance
of the problem in the dark. The problem of con-
taminated cell lines has been addressed previ-
ously by 1 of us40 as well as by others in more
recent editorial articles in Science and several
other journals.20–22 A recent study16 examined
reports in the literature of the TP53 mutational
status from different investigators who studied
the cells that are included in the National Can-
cer Institute panel of 60 representative human
tumor cell lines. The authors reported finding
discrepancies in the reported TP53 mutation
status for 13 of 60 cell lines (22%) included in
this important repository. Their findings suggest
that different versions of the cell lines are being
used in various laboratories and that they may
not be the cell line the investigators think they
are using.
Because it is necessary to reliably genotype
cells that have been cultured in independent
laboratories for multiple years, several studies
have focused on the reproducibility of microsa-
tellite genotyping by studying long-term micro-
satellite stability. For example, Masters et al23
analyzed HeLa cells that had been cultured in-
dependently by different labs over several years
and found both gains and losses of alleles. How-
ever, only a few alleles were altered in each
case, and, because of the consistency between
the other alleles, the cell lines were still able to
be identified as HeLa with very high probability.
Likewise, the group analyzed the genotypes of
cell lines derived by in vitro selection by long-
term exposure to chemotherapy, and found that
the differences between the STR loci were no
greater than those between HeLa cells that had
been independently cultured.23 Despite the fact
that cell lines can be identified after long peri-
ods of independent culturing, phenotypic differ-
ences arise in different laboratories because cell
lines evolve in vitro, likely leading to the
increased growth potential. As such, cell lines
should be periodically refreshed from the low-
passage stocks.
With the intense demand for the UM-SCC
head and neck cancer cell lines from colleagues
around the world, and a desire to ensure that
results from multiple labs could be compared,
we took advantage of the availability of rapid,
low-cost, highly polymorphic microsatellite anal-
ysis to genotype our entire University of Michi-
gan cell line panel. Like others before us, we
were chagrined to find that over time mistakes
had been made and mislabeling of cell lines had
occurred even within our own cell line bank.
Because ours is a laboratory that stresses good
principles of tissue culture, this example shows
how easily mistakes can be made and perpetu-
ated in cell culture studies. Table 1 from this ar-
ticle and representative photographs of each of
our generically characterized cell lines will
be posted on the University of Michigan Head
and Neck Cancer SPORE (Specialized Project
of Research Excellence) web page for easy
access for other investigators who have these
lines in their laboratory. See also Supplemental
Material.
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